Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era.

Shinar Y, Ceccherini I, Rowczenio D, Aksentijevich I, Arostegui J, Ben-Chétrit E, Boursier G, Gattorno M, Hayrapetyan H, Ida H, Kanazawa N, Lachmann HJ, Mensa-Vilaro A, Nishikomori R, Oberkanins C, Obici L, Ohara O, Ozen S, Sarkisian T, Sheils K, Wolstenholme N, Zonneveld-Huijssoon E, van Gijn ME, Touitou I.

Clin Chem. 2020 Apr 1;66(4):525-536. doi: 10.1093/clinchem/hvaa024.

PMID:
32176780
2.

Discovering the Italian phenotype of cerebral amyloid angiopathy (CAA): the SENECA project.

Bersano A, Scelzo E, Pantoni L, Morotti A, Erbetta A, Chiapparini L, Vitali P, Giaccone G, Caroppo P, Catania M, Obici L, Di Fede G, Gatti L, Tinelli F, Di Francesco JC, Piazza F, Ferrarese C, Gasparini M, Adobbati L, Bianchi-Marzoli S, Tremolada G, Sacco S, Mancuso M, Zedde ML, Godani M, Lanfranconi S, Pareyson D, Di Girolamo M, Motto C, Charidimou A, Boulouis G, Parati EA; SENECA project.

Neurol Sci. 2020 Mar 12. doi: 10.1007/s10072-020-04306-8. [Epub ahead of print]

PMID:
32166471
3.

Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.

Obici L, Berk JL, González-Duarte A, Coelho T, Gillmore J, Schmidt HH, Schilling M, Yamashita T, Labeyrie C, Brannagan TH 3rd, Ajroud-Driss S, Gorevic P, Kristen AV, Franklin J, Chen J, Sweetser MT, Wang JJ, Adams D.

Amyloid. 2020 Mar 4:1-10. doi: 10.1080/13506129.2020.1730790. [Epub ahead of print]

PMID:
32131641
4.

Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy.

Maia LF, Maceski A, Conceição I, Obici L, Magalhães R, Cortese A, Leppert D, Merlini G, Kuhle J, Saraiva MJ.

Amyloid. 2020 Jan 6:1-6. doi: 10.1080/13506129.2019.1708716. [Epub ahead of print]

PMID:
31906707
5.

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.

Coelho T, Yarlas A, Waddington-Cruz M, White MK, Sikora Kessler A, Lovley A, Pollock M, Guthrie S, Ackermann EJ, Hughes SG, Karam C, Khella S, Gertz M, Merlini G, Obici L, Schmidt HH, Polydefkis M, Dyck PJB, Brannagan Iii TH, Conceição I, Benson MD, Berk JL.

J Neurol. 2020 Apr;267(4):1070-1079. doi: 10.1007/s00415-019-09671-9. Epub 2019 Dec 18.

6.

Amyloidosis in Heart Failure.

Ihne S, Morbach C, Obici L, Palladini G, Störk S.

Curr Heart Fail Rep. 2019 Dec;16(6):285-303. doi: 10.1007/s11897-019-00446-x. Review.

PMID:
31782077
7.

Light Chains With Heavy Effects.

Obici L, Merlini G.

Am J Kidney Dis. 2020 Feb;75(2):291-293. doi: 10.1053/j.ajkd.2019.08.009. Epub 2019 Oct 16. No abstract available.

PMID:
31629574
8.

An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis.

Milani P, Mussinelli R, Perlini S, Palladini G, Obici L.

Expert Opin Pharmacother. 2019 Dec;20(18):2223-2228. doi: 10.1080/14656566.2019.1671352. Epub 2019 Sep 30. Review.

PMID:
31566422
9.

Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis.

Obici L, Suhr OB.

Clin Auton Res. 2019 Sep;29(Suppl 1):55-63. doi: 10.1007/s10286-019-00628-6. Epub 2019 Aug 26. Review.

10.

Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.

Dyck PJB, González-Duarte A, Obici L, Polydefkis M, Wiesman JF, Antonino I, Litchy WJ, Dyck PJ.

J Neurol Sci. 2019 Oct 15;405:116424. doi: 10.1016/j.jns.2019.116424. Epub 2019 Aug 8. Review.

11.

Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers.

Papa R, Rusmini M, Volpi S, Caorsi R, Picco P, Grossi A, Caroli F, Bovis F, Musso V, Obici L, Castana C, Ravelli A, Van Gijn ME, Ceccherini I, Gattorno M.

Rheumatology (Oxford). 2020 Feb 1;59(2):458. doi: 10.1093/rheumatology/kez376. No abstract available.

PMID:
31410474
12.

Assessment of patients with hereditary transthyretin amyloidosis - understanding the impact of management and disease progression.

Conceição I, Coelho T, Rapezzi C, Parman Y, Obici L, Galán L, Rousseau A.

Amyloid. 2019 Sep;26(3):103-111. doi: 10.1080/13506129.2019.1627312. Epub 2019 Jul 24. Review.

PMID:
31339362
13.

Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers.

Papa R, Rusmini M, Volpi S, Caorsi R, Picco P, Grossi A, Caroli F, Bovis F, Musso V, Obici L, Castana C, Ravelli A, Van Gijn ME, Ceccherini I, Gattorno M.

Rheumatology (Oxford). 2020 Feb 1;59(2):344-360. doi: 10.1093/rheumatology/kez270.

PMID:
31325311
14.

Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.

Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, Gospodinova M, Obici L, Rapezzi C, Garcia-Pavia P.

JACC Heart Fail. 2019 Aug;7(8):709-716. doi: 10.1016/j.jchf.2019.04.010. Epub 2019 Jul 10. Review.

15.

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.

Gertz MA, Scheinberg M, Waddington-Cruz M, Heitner SB, Karam C, Drachman B, Khella S, Whelan C, Obici L.

Expert Rev Clin Pharmacol. 2019 Aug;12(8):701-711. doi: 10.1080/17512433.2019.1635008. Epub 2019 Jul 3. Review.

PMID:
31268366
16.

A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors.

Bertoni A, Carta S, Baldovini C, Penco F, Balza E, Borghini S, Di Duca M, Ognio E, Signori A, Nozza P, Schena F, Castellani P, Pastorino C, Perrone C, Obici L, Martini A, Ceccherini I, Gattorno M, Rubartelli A, Chiesa S.

J Allergy Clin Immunol. 2020 Jan;145(1):368-378.e13. doi: 10.1016/j.jaci.2019.05.034. Epub 2019 Jun 10.

PMID:
31194989
17.

Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

Lucherini OM, Vitale A, Obici L, Sota J, Frediani B, Merlini G, Rigante D, Cantarini L.

Clin Exp Rheumatol. 2019 Nov-Dec;37 Suppl 121(6):159-160. Epub 2019 May 30. No abstract available.

18.

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients.

Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, Nuvolone M, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini G, Palladini G, Lavatelli F.

Blood. 2019 Jul 18;134(3):320-323. doi: 10.1182/blood.2019000420. Epub 2019 Jun 6. No abstract available.

PMID:
31171502
19.

Burden of hereditary transthyretin amyloidosis on quality of life.

Yarlas A, Gertz MA, Dasgupta NR, Obici L, Pollock M, Ackermann EJ, Lovley A, Kessler AS, Patel PA, White MK, Guthrie SD.

Muscle Nerve. 2019 Aug;60(2):169-175. doi: 10.1002/mus.26515. Epub 2019 Jun 13.

20.

Classification criteria for autoinflammatory recurrent fevers.

Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, Anton J, Arostegui JI, Barron K, Ben-Cherit E, Brogan PA, Cantarini L, Ceccherini I, De Benedetti F, Dedeoglu F, Demirkaya E, Frenkel J, Goldbach-Mansky R, Gul A, Hentgen V, Hoffman H, Kallinich T, Kone-Paut I, Kuemmerle-Deschner J, Lachmann HJ, Laxer RM, Livneh A, Obici L, Ozen S, Rowczenio D, Russo R, Shinar Y, Simon A, Toplak N, Touitou I, Uziel Y, van Gijn M, Foell D, Garassino C, Kastner D, Martini A, Sormani MP, Ruperto N; Eurofever Registry and the Paediatric Rheumatology International Trials Organisation (PRINTO).

Ann Rheum Dis. 2019 Aug;78(8):1025-1032. doi: 10.1136/annrheumdis-2019-215048. Epub 2019 Apr 24. Review.

PMID:
31018962
21.

Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.

Buxbaum JN, Brannagan T 3rd, Buades-Reinés J, Cisneros E, Conceicao I, Kyriakides T, Merlini G, Obici L, Plante-Bordeneuve V, Rousseau A, Sekijima Y, Imai A, Waddington Cruz M, Yamada M.

Amyloid. 2019 Mar;26(1):10-14. doi: 10.1080/13506129.2018.1554563. Epub 2019 Jan 24.

PMID:
30675806
22.

Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.

Kristen AV, Ajroud-Driss S, Conceição I, Gorevic P, Kyriakides T, Obici L.

Neurodegener Dis Manag. 2019 Feb;9(1):5-23. doi: 10.2217/nmt-2018-0033. Epub 2018 Nov 27.

23.

Seek and You Shall Find: Is Subclinical Amyloid More Common Than Expected?

Obici L, Merlini G.

Mayo Clin Proc. 2018 Nov;93(11):1546-1548. doi: 10.1016/j.mayocp.2018.09.008. No abstract available.

PMID:
30392540
24.

An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome.

Federici S, Vanoni F, Ben-Chetrit E, Cantarini L, Frenkel J, Goldbach-Mansky R, Gul A, Hoffman H, Koné-Paut I, Kuemmerle-Deschner J, Lachmann HJ, Martini A, Obici L, Ozen S, Simon A, Hofer M, Ruperto N, Gattorno M; Eurofever and the Pediatric Rheumatology International Trials Organization (PRINTO).

J Rheumatol. 2019 Apr;46(4):429-436. doi: 10.3899/jrheum.180056. Epub 2018 Nov 1.

PMID:
30385706
25.

Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy.

Obici L.

Arq Neuropsiquiatr. 2018 Sep;76(9):573-574. doi: 10.1590/0004-282X20180102. No abstract available.

26.

Progressive axonal polyneuropathy in a mitochondrial disorder: an uncommon association with familial amyloid neuropathy.

Luigetti M, Primiano G, Bisogni G, Cuccagna C, Carrozzo R, Obici L, Bernardo D, Sancricca C, Servidei S.

Amyloid. 2018 Dec;25(4):261-262. doi: 10.1080/13506129.2018.1506919. Epub 2018 Sep 7. No abstract available.

PMID:
30193540
27.

Plasminogen activation triggers transthyretin amyloidogenesis in vitro.

Mangione PP, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S, Raimondi S, Stoppini M, Esposito M, Relini A, Canale C, Valli M, Marchese L, Faravelli G, Obici L, Hawkins PN, Taylor GW, Gillmore JD, Pepys MB, Bellotti V.

J Biol Chem. 2018 Sep 14;293(37):14192-14199. doi: 10.1074/jbc.RA118.003990. Epub 2018 Jul 17.

28.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T.

N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.

29.

Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.

De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G.

N Engl J Med. 2018 May 17;378(20):1908-1919. doi: 10.1056/NEJMoa1706314.

30.

Renal involvement in autoinflammatory diseases and inflammasome-mediated chronic kidney damage.

Scarpioni R, Obici L.

Clin Exp Rheumatol. 2018 Jan-Feb;36 Suppl 110(1):54-60. Epub 2018 May 3. Review.

31.

Autoinflammatory diseases as a cause of acute abdominal pain in the emergency department.

Maconi G, Obici L, Carmagnola S, Guzzetti S.

Clin Exp Rheumatol. 2018 Jan-Feb;36 Suppl 110(1):39-43. Epub 2018 May 3. Review.

32.

Updated overview of molecular pathways involved in the most common monogenic autoinflammatory diseases.

Lucherini OM, Rigante D, Sota J, Fabiani C, Obici L, Cattalini M, Gattorno M, Cantarini L.

Clin Exp Rheumatol. 2018 Jan-Feb;36 Suppl 110(1):3-9. Epub 2018 May 3. Review.

33.

Cryopyrin-associated Periodic Syndromes in Italian Patients: Evaluation of the Rate of Somatic NLRP3 Mosaicism and Phenotypic Characterization.

Lasigliè D, Mensa-Vilaro A, Ferrera D, Caorsi R, Penco F, Santamaria G, Di Duca M, Amico G, Nakagawa K, Antonini F, Tommasini A, Consolini R, Insalaco A, Cattalini M, Obici L, Gallizzi R, Santarelli F, Del Zotto G, Severino M, Rubartelli A, Ravazzolo R, Martini A, Ceccherini I, Nishikomori R, Gattorno M, Arostegui JI, Borghini S.

J Rheumatol. 2017 Nov;44(11):1667-1673. doi: 10.3899/jrheum.170041. Epub 2017 Sep 15.

PMID:
28916543
34.

Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system.

Gonçalves NP, Moreira J, Martins D, Vieira P, Obici L, Merlini G, Saraiva M, Saraiva MJ.

J Neuroinflammation. 2017 Jun 6;14(1):115. doi: 10.1186/s12974-017-0891-9.

35.

Prognostication of survival and progression to dialysis in AA amyloidosis.

Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, Foli A, Lavatelli F, Nuvolone M, Casarini S, Obici L, Merlini G.

Amyloid. 2017 Mar;24(sup1):136-137. doi: 10.1080/13506129.2017.1289917. No abstract available.

PMID:
28434292
36.

Circulating intercellular adhesion molecule 1 (sICAM-1) in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

Cantarini L, Pucino V, Vitale A, Lucherini OM, Obici L, Matarese G.

Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 104(2):13-14. Epub 2017 Apr 4. No abstract available.

37.

Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy.

Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, Merlini G, Obici L.

J Neurol Neurosurg Psychiatry. 2017 May;88(5):457-458. doi: 10.1136/jnnp-2016-315262. Epub 2017 Feb 10. No abstract available.

38.

Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney.

Obici L, Nuvolone M, Merlini G.

Kidney Int. 2016 Sep;90(3):479-81. doi: 10.1016/j.kint.2016.05.029.

PMID:
27521110
39.

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.

Torene R, Nirmala N, Obici L, Cattalini M, Tormey V, Caorsi R, Starck-Schwertz S, Letzkus M, Hartmann N, Abrams K, Lachmann H, Gattorno M.

Ann Rheum Dis. 2017 Jan;76(1):303-309. doi: 10.1136/annrheumdis-2016-209335. Epub 2016 Jul 29.

40.

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.

Schmidt HH, Barroso F, González-Duarte A, Conceição I, Obici L, Keohane D, Amass L.

Muscle Nerve. 2016 Sep;54(3):353-60. doi: 10.1002/mus.25210.

41.

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.

Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, Speziale A, Bhansali SG, Martini A, Lachmann HJ.

Ann Rheum Dis. 2017 Jan;76(1):173-178. doi: 10.1136/annrheumdis-2015-209031. Epub 2016 Jun 7.

42.

Clinical Pregenetic Screening for Stroke Monogenic Diseases: Results From Lombardia GENS Registry.

Bersano A, Markus HS, Quaglini S, Arbustini E, Lanfranconi S, Micieli G, Boncoraglio GB, Taroni F, Gellera C, Baratta S, Penco S, Mosca L, Grasso M, Carrera P, Ferrari M, Cereda C, Grieco G, Corti S, Ronchi D, Bassi MT, Obici L, Parati EA, Pezzini A, De Lodovici ML, Verrengia EP, Bono G, Mazucchelli F, Zarcone D, Calloni MV, Perrone P, Bordo BM, Colombo A, Padovani A, Cavallini A, Beretta S, Ferrarese C, Motto C, Agostoni E, Molini G, Sasanelli F, Corato M, Marcheselli S, Sessa M, Comi G, Checcarelli N, Guidotti M, Uccellini D, Capitani E, Tancredi L, Arnaboldi M, Incorvaia B, Tadeo CS, Fusi L, Grampa G, Merlini G, Trobia N, Comi GP, Braga M, Vitali P, Baron P, Grond-Ginsbach C, Candelise L; Lombardia GENS Group*.

Stroke. 2016 Jul;47(7):1702-9. doi: 10.1161/STROKEAHA.115.012281. Epub 2016 May 31.

PMID:
27245348
43.

Erratum to: Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.

Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.

J Neurol. 2016 May;263(5):925-926. doi: 10.1007/s00415-016-8116-1. No abstract available.

PMID:
27098978
44.

Clinical Characteristics of Patients Carrying the Q703K Variant of the NLRP3 Gene: A 10-year Multicentric National Study.

Naselli A, Penco F, Cantarini L, Insalaco A, Alessio M, Tommasini A, Maggio C, Obici L, Gallizi R, Cimmino M, Signa S, Lucherini OM, Carta S, Caroli F, Martini A, Rubartelli A, Ceccherini I, Gattorno M.

J Rheumatol. 2016 Jun;43(6):1093-100. doi: 10.3899/jrheum.150962. Epub 2016 Apr 1.

PMID:
27036377
45.

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.

Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M, Manganelli F, Santoro L, Cavallaro T, Fabrizi GM, Schenone A, Grandis M, Gemelli C, Mauro A, Pradotto LG, Gentile L, Stancanelli C, Lozza A, Perlini S, Piscosquito G, Calabrese D, Mazzeo A, Obici L, Pareyson D.

J Neurol. 2016 May;263(5):916-924. doi: 10.1007/s00415-016-8064-9. Epub 2016 Mar 16. Erratum in: J Neurol. 2016 May;263(5):925-926.

PMID:
26984605
46.

Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.

Obici L, Kuks JB, Buades J, Adams D, Suhr OB, Coelho T, Kyriakides T; European Network for TTR-FAP (ATTReuNET).

Curr Opin Neurol. 2016 Feb;29 Suppl 1:S27-35. doi: 10.1097/WCO.0000000000000290. Review.

47.

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.

Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, Slama MS, Hazenberg BP, Coelho T; European Network for TTR-FAP (ATTReuNET).

Curr Opin Neurol. 2016 Feb;29 Suppl 1:S14-26. doi: 10.1097/WCO.0000000000000289. Review.

48.

Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP.

Parman Y, Adams D, Obici L, Galán L, Guergueltcheva V, Suhr OB, Coelho T; European Network for TTR-FAP (ATTReuNET).

Curr Opin Neurol. 2016 Feb;29 Suppl 1:S3-S13. doi: 10.1097/WCO.0000000000000288. Review.

49.

"Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.

Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, Amass L.

J Peripher Nerv Syst. 2016 Mar;21(1):5-9. doi: 10.1111/jns.12153. Review.

50.

Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome.

Pucino V, Lucherini OM, Perna F, Obici L, Merlini G, Cattalini M, La Torre F, Maggio MC, Lepore MT, Magnotti F, Galgani M, Galeazzi M, Marone G, De Rosa V, Talarico R, Cantarini L, Matarese G.

J Leukoc Biol. 2016 May;99(5):761-9. doi: 10.1189/jlb.3A0915-399R. Epub 2015 Nov 23.

PMID:
26598380

Supplemental Content

Support Center